IndiaCatalog.com
Login Signup
IndiaCatalog.com
Home Web Directory Classifieds Yellow Pages Global Directory City Guide News Photo Galleries
Login
Signup
  • Home
  • Global Web Directory
  • Drugs
Biotechnology
Diagnostic Substances
Drug Delivery
Drug Manufacturers - Major
Drug Manufacturers - Other
Drug Related Products
Drugs - Generic

Vermillion, Inc.

Vermillion, Inc.

Vermillion, Inc. is involved in the discovery, development and commercialization of diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. The Company uses the process of utilizing advanced protein separation methods to identify and resolve variants of specific biomarkers (known as translational proteomics) for developing a procedure to measure a property or concentration of an analyte (known as an assay) and commercializing diagnostic tests. Vermillion has focuses in the areas of oncology, hematology, cardiology and women’s health. Vermillion’s focus on translational proteomics enables it to address the market for diagnostic tests that measure multiple protein biomarkers. In January 2010, the Company emerged from protection under Chapter 11 of the United States Bankruptcy Code.

Amgen GmbH

Amgen GmbH

Amgen GmbH speaks the language of biotech geeks, only with a German accent. Amgen GmbH is a German unit of US-based Amgen, the world's largest biotech company. The subsidiary was established in 1989 to help sell and distribute biotechnical therapies for the treatment of such ailments as chemotherapy side effects, chronic kidney failure, and rheumatoid arthritis. Among the group's products are Epogen and Aranesp, for the treatment of anemia in people with chronic kidney disease; Neupogen and Neulasta, to help restore white blood cell counts for cancer patients; and Enbrel, for the treatment of psoriasis and rheumatoid arthritis.

Actelion Pharmaceuticals UK Ltd.

Actelion Pharmaceuticals UK Ltd.

Actelion Pharmaceuticals UK is the British arm of Swiss biotech firm Actelion. The drug manufacturer's product pipeline is based on its research of the endothelium, the single layer of cells between blood vessels and the blood that flows through them. Its first products are Tracleer for the treatment of pulmonary arterial hypertension, and Zavesca which is used to treat Type 1 Gaucher disease.

Genta Incorporated

Genta Incorporated

Genta plays rough with cancer. The firm develops drugs, including DNA/RNA medicines and more traditional small molecule drugs, for cancer and other diseases. Lead candidate Genasense blocks production of a protein that can cause resistance to cancer treatments. The company is hoping for marketing approval of Genasense to be used in conjunction with chemotherapy by patients with lymphocytic leukemia and malignant melanoma. Genasense is also in clinical trials for treatment of other diseases, such as prostate and colon cancer. Its small molecule program yielded Ganite, an FDA-approved treatment for hypercalcemia (a potentially fatal side effect of cancer); but the company does not actively market the drug.

Avexa Limited

Avexa Limited

Avexa discovers drugs to treat vexing ailments. The pharmaceutical and research company works on the discovery and development of drugs for the treatment of infectious diseases, specifically HIV and antibiotic-resistant strains of bacteria. Avexa has worked on collaborative projects with Victorian College of Pharmacy, The Shanghai Institute of Organic Chemistry, North Carolina State University, and Georgetown University, among other institutions. The company was formed in 2004 when it was spun off from Australian drug discovery and biotechnology development company Amrad. Plans to merge with drugmaker Progen Pharmaceutical were canceled in 2009.

SCOLR Pharma Inc.

SCOLR Pharma Inc.

SCOLR Pharma, Inc. is a specialty pharmaceutical company, which through its Controlled Delivery Technology (CDT) platforms, develops prescription, over-the-counter (OTC) and nutritional products. The Company has developed multiple private-label controlled release nutritional products incorporating its CDT platforms that are sold by national retailers. The Company’s lead product candidate is a CDT-based controlled release formulation of ibuprofen, an analgesic used for the treatment of pain, fever and inflammation. It completed the pivotal phase III trial to evaluate the safety and efficacy of its 12 hour CDT 600 milligram controlled release ibuprofen for the OTC market. In addition, the Company submitted its first abbreviated new drug application (ANDA) for its 12-hour pseudoephedrine product on August 5, 2008.

Diagnostic HYBRIDS, Inc.

Diagnostic HYBRIDS, Inc.

Diagnostic HYBRIDS was founded in 1983 by Ohio University professors and private investor and entrepreneur Dr. Wilfred Konneker. It has agreed to be acquired by Quidel for $130 million. Diagnostic HYBRIDS will tell you which kind you have. The company develops and markets cell culture kits to help identify various viruses and endocrine diseases. Its product line include kits to detect a wide range of influenza viruses, herpes simplex viruses 1 and 2, Chlamydia and Cytomegalovirus, which includes the viruses that cause chicken pox and mononucleosis. Other kits demonstrate thyroid functioning. The biotech firm also develops and sells cell-based detection products.

Teikoku Pharma USA, Inc.

Teikoku Pharma USA, Inc.

Teikoku Pharma USA is a wholly-owned subsidiary of Teikoku Seiyaku Inc., a specialty pharmaceutical company that develops, and manufactures enhanced pharmaceutical products based on its transdermal drug delivery technologies. Teikoku focuses its efforts in two therapeutic areas; Pain and CNS. By applying our transdermal technologies to existing actives or co-developing new formulations, Teikoku helps pharmaceutical companies extend patent protections, diversify product lines, provide better delivery mechanisms, and promote brand loyalty. Teikoku charts new territory in prescription, OTC, and medical device markets around the world, transforming ideas into ideally delivered products that carry a competitive edge in quality and innovation.

Optimer Pharmaceuticals, Inc.

Optimer Pharmaceuticals, Inc.

Optimer Pharmaceuticals was founded in 1998 and is based in San Diego, California. Optimer Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing anti-infective products worldwide. The company develops products that treat gastrointestinal infections and related diseases. Its two late-stage anti-infective product candidates include Fidaxomicin, the lead product candidate and an antibiotic that is in second Phase III registration trial for the treatment of clostridium difficile-infections; and Prulifloxacin, a prodrug in the fluoroquinolone class of antibiotics, which completed second Phase III trials for the treatment of infectious diarrhea in travelers. It also develops OP-1068/CEM-101, an antibiotic for the treatment of upper and lower respiratory tract infections; OPT-88, a disease-modifying intra-articular, or within the cavity of a joint, therapy for osteoarthritis; OPT-822, a carbohydrate-based cancer immunotherapy for the treatment of metastatic breast cancer; and an OPopS drug discovery platform. The company has a collaborative research and development, and license agreement with Cempra Pharmaceuticals, Inc. to discover, develop, and commercialize drugs based on macrolide and ketolide compounds.

Agennix AG

Agennix AG

Agennix develops oral, topical, and other forms of cancer treatments. The company's primary candidate, Talactoferrin, is an oral therapy in the late stages of development that is targeted to treat non-small cell lung cancer, a common and slow-growing type of lung cancer. Its other clinical development-stage candidates include therapies to treat tumors and prostate cancer, as well as non-cancerous conditions such as sepsis and diabetic foot ulcers. Agennix, which has offices in Munich, Germany; Princeton, New Jersey; and Houston, Texas, was formed in 2009 from the merger of Germany-based GPC Biotech AG and US-based Agennix Inc.

Post a FREE Classified Advertisement

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.

Most Read News

IndiaCatalog News
Nestle CEO, management under pressure as infant formula crisis adds to woes
IndiaCatalog News
Cong alleges use of benami funds to amass large stakes in Adani Group
IndiaCatalog News
Microsoft to invest $50 bn to expand AI to countries across 'Global South'
IndiaCatalog News
ECI announces schedule for biennial Rajya Sabha polls across 10 states
IndiaCatalog News
Reliance to invest ₹10 trillion in AI over next 7 years: Mukesh Ambani

CORPORATE NEWS

N I I T
N I I T
DLF Ltd
DLF Ltd
Unitech Limited
Unitech Limited
GMR Group
GMR Group
BHEL
BHEL
Yes Bank
Yes Bank
NTPC Limited
NTPC Limited
Indian Oil Corporation
Indian Oil Corporation
IndiaCatalog.com

IndiaCatalog.com is a website brought to you by Portland Technologies to provide directory of Indian websites, News, City Guides and profiles of Indian Businesses. Portland Technologies also provides IT solutions for Small and Medium Businesses in India.


Products

India Web Directory

Global Web Directory

Yellow Pages

Photo Galleries

FREE India Classifieds


Useful links

About us

Advertise

Link to us

Submit a Site

Business Reviews


Contact

Plot #37, Ramnagar Gundu, Hyderabad - 500 044

service@indiacatalog.com

+91-40-23756949


© Copyright: IndiaCatalog.com